乙二醛酶1通过调控Sox2转录网络促进胶质瘤干细胞样细胞驱动的肿瘤进展
该研究利用单细胞转录组学、功能基因组学、体外实验及患者来源异种移植(PDX)和子宫内电转(IUE)胶质母细胞瘤(GBM)模型,发现乙二醛酶1(Glo1)在胶质瘤干细胞样细胞(GSC)中富集,通过调控Sox2活性维持GSC增殖和肿瘤进展;遗传或药理抑制Glo1可降低GSC活力、抑制肿瘤生长并延长生存期,提示Glo1是GSC导向治疗的潜在靶点。
要点
- Glo1在GSC中富集并促进GSC增殖与肿瘤进展,与不良预后相关。
- 药理抑制Glo1可降低GSC活力、抑制肿瘤生长并延长PDX和IUE-GBM模型生存期。
- Glo1部分通过调控Sox2活性影响GSC维持相关的转录程序。
核心结论
- Glo1是GSC生物学行为的关键调控因子,靶向Glo1可能成为GBM中GSC导向治疗的新策略。
研究设计与样本
- 研究采用单细胞转录组学、功能基因组学、体外实验以及患者来源异种移植(PDX)和子宫内电转(IUE)胶质母细胞瘤(GBM)模型。
- 通过遗传过表达、敲低和药理抑制三种方式操控Glo1。
主要发现
- Glo1在人和小鼠GBM模型的单细胞转录组分析中被鉴定,富集于以干性标志物定义的GSC群体。
- 遗传操控Glo1表明其促进GSC增殖和肿瘤进展,并与不良预后相关。
- 药理抑制Glo1显著降低GSC活力和肿瘤生长,并在PDX和IUE-GBM模型中延长生存期。
- 机制上,Glo1调控部分通过调节Sox2活性破坏与GSC维持相关的转录程序。
临床怎么用
- Glo1可作为GSC相关标志物用于功能研究,并作为GBM靶向治疗的候选靶点。
- 药理抑制Glo1在临床前模型中显示可抑制GSC活力和肿瘤生长并延长生存,支持进一步转化研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioma stem-like cells (GSCs) contribute to tumor heterogeneity and are resistant to conventional therapies, making them a significant obstacle to achieving long-term treatment success. However, efforts to eliminate GSCs have been hindered by the lack of reliable markers that provide functional insight into these processes. Therefore, identifying GSC-associated markers is critical for understanding glioma tumorigenesis and for developing targeted therapeutic strategies that can effectively suppress tumor progression and recurrence. METHODS: We employed single-cell transcriptomics, functional genomics, in vitro assays, and preclinical glioblastoma (GBM) models, including patient-derived xenografts (PDXs) and in utero electroporation (IUE)-based models, to investigate the role of Glyoxalase 1 (Glo1) in GSCs and GBM. Manipulation of Glo1 was achieved through genetic overexpression, knockdown, and pharmacological inhibition. RESULTS: Glyoxalase 1 was initially identified through integrative single-cell transcriptomic analyses of human and mouse GBM models, where it is enriched in GSC populations defined by stemness markers. Genetic manipulation of Glo1 indicates that it promotes GSC proliferation and tumor progression, while also being associated with poor prognosis. In addition, pharmacological inhibition of Glo1 significantly reduced GSC viability and tumor growth, and prolonged survival in both PDX and IUE-GBM models. Mechanistically, Glo1 modulation disrupted transcriptional programs associated with GSC maintenance, in part by modulating Sox2 activity. CONCLUSIONS: These findings demonstrate Glo1 as a key regulator of GSC biology and highlight its potential as a therapeutic target for GSC-directed intervention in GBM. Targeting Glo1 may offer a novel strategy to impair GSC-driven tumor progression and improve GBM treatment outcomes. Glioblastoma (GBM) is an aggressive brain tumor containing a subpopulation of glioma stem-like cells (GSCs) that drive tumor growth and therapy resistance. Despite the crucial role of GSCs in GBM progression, therapeutic strategies targeting them remain elusive. Here, we identify Glyoxalase 1 (Glo1) as a critical regulator of GSC identity and function. Genetic and pharmacological inhibition of Glo1 impairs GSC viability and tumor growth, while prolonging survival in preclinical models of GBM. Mechanistically, Glo1 modulation altered transcriptional programs associated with GSC self-renewal. Collectively, these findings uncover Glo1 as a key regulator of GSCs in GBM and highlight it as a prospective therapeutic target for GSC-directed therapy in GBM.
引用
- Choi DJ, Ko Y, He P, et al. Glyoxalase 1 promotes glioma progression by modulating Sox2 transcriptional networks in glioma stem-like cells. Neuro Oncol. 2026. PMID: 42011505. doi:10.1093/neuonc/noag090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。